Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting
Survival benefit observed in two treatment settings of previously treated non-small lung cancer patients
June 04, 2021 09:00 ET | Source: Heat Biologics Heat Biologics Morrisville, North Carolina, UNITED STATES
DURHAM, N.C., June 04, 2021 (GLOBE NEWSWIRE) Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Dr. Roger B. Cohen, MD, Professor of Medicine at the University of Pennsylvania Perelman School of Medicine, presented an overview of the latest HS-110 data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting which is being held from June 4-8, 2021. This poster presentation can be viewed on Heat Biologi
United-states
American
Rogerb-cohen
American-society-of-clinical-oncology
University-of-pennsylvania-perelman-school-medicine
Heat-biologics-inc
Nasdaq
Pennsylvania-perelman-school
Clinical-oncology
Annual-meeting
Heat-biologic